title: [Sandostatin treatment of destructive pancreatitis].
abstract: Sandostatin has been used in combined treatment of 30 patients with destructive pancreatitis in a dose 200-600 micrograms/day subcutaneously. The drug significantly depressed production of enzyme toxins in the pancreas but failed to prevent widening of necrotic zones and progression of the process in the retroperitoneal fat. The duration of sandostatin treatment should not be longer than 5-7 days. If no response is achieved for this time, surgical treatment is indicated. It is not reasonable to reject conventional drugs used in acute destructive pancreatitis for sandostatin monotherapy.
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Ivanov
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide
vernacular_title: O lechenii destruktivnogo pankreatita sandostatinom.